Trials / Completed
CompletedNCT05241535
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
A Phase 1, Randomized, Partial Double-Blind, Placebo- and Positive-Controlled, Three-way Crossover Study to Evaluate the Effect of MT-7117 on the QT/QTc Interval in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Tanabe Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-7117 | oral |
| DRUG | moxifloxacin | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2022-01-12
- Primary completion
- 2022-02-23
- Completion
- 2022-02-27
- First posted
- 2022-02-15
- Last updated
- 2023-05-15
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05241535. Inclusion in this directory is not an endorsement.